SOX10作为原发性口腔黏膜恶性黑色素瘤分子诊断指标的初步研究

doi:10.3969/j.issn.1005-4979.2019.03.002

摘要/Abstract

摘要： 目的：阐明SOX10在口腔黏膜恶性黑色素瘤的表达特点。方法：通过免疫组织化学染色对89例口腔黏膜恶性黑色素瘤（OMM）及4例口腔黏膜促结缔组织增生型黑色素瘤(ODM) 的石蜡标本中，S-100、HMB-45、Melan-A以及SOX10的表达特点进行分析。结果：在OMM中Melan-A、HMB-45、S-100以及SOX10的表达水平分别为96.6%、93.3%、97.8%及98.8%。在OMM中SOX10的表达水平与S-100、Melan-A无明显统计学差异（P＞0.05），但显著高于HMB-45（P＜0.05）。在4例ODM中，SOX10与S-100均表达，Melan-A及HMB-45表达均阴性。在OMM及ODM中，SOX10的染色模式均呈强且特异的核染。结论：SOX10可在S-100、Melan-A，HMB-45等常规免疫组化标记物的基础上，作为OMM及ODM病理诊断的有力补充，具有重要的临床应用价值。

关键词: SOX10； , 口腔黏膜恶性黑色素瘤； , 分子诊断；组织病理学； , 免疫组织化学

Abstract: Objective: To elucidate the expression of SOX10 in primary oral mucosal melanoma (OMM). Methods: The expression of S-100, HMB-45, Melan-A and SOX10 in 89 OMM and 4 ODM(oral mucosal desmoplastic melanoma) in paraffin specimens were analyzed by immunohistochemical staining. Results: In OMM, the expression levels of Melan-A,HMB-45, S-100 and SOX10 were 96.6%, 93.3%, 97.8% and 98.8%, respectively. The expression level of SOX10 in OMM was not significantly different from S-100 and Melan-A (P＞0.05), but significantly higher than that of HMB-45 (P＜0.05). In 4 ODM cases, SOX10 and S-100 were expressed, while Melan-A and HMB-45 were negative. In OMM and ODM, the staining pattern of SOX10 was strong and specific was present in nuclear. Conclusions: SOX10 could be used as a helpful marker for pathological diagnosis of OMM and ODM on the basis of routine immunohistochemical markers, such as S-100, Melan-A and HMB-45, and is of significant clinical importance.

Key words: SOX10, primary oral mucosal melanoma (OMM), molecular diagnosis, histopathology, immunohistochemistry

中图分类号:

R782.4

马旭辉，王丽珍，任国欣，吴云腾，顾挺，郭伟. SOX10作为原发性口腔黏膜恶性黑色素瘤分子诊断指标的初步研究[J]. 《口腔颌面外科杂志》, doi: 10.3969/j.issn.1005-4979.2019.03.002.

MA Xu hui, WANG Li zheng, REN Guo xin, WU Yun teng, GU Ting, GUO Wei. A Preliminary Study on SOX10 as A Molecular Diagnostic Marker for Primary Oral Mucosal Melanoma[J]. 《Journal of Oral and Maxillofacial Surgery》, doi: 10.3969/j.issn.1005-4979.2019.03.002.

https://journal06.magtech.org.cn/Jweb_joms/CN/Y2019/V29/I3/131

参考文献

[1] 吴云腾, 任国欣, 孙沫逸, 等. 中国头颈黏膜黑色素瘤临床诊治专家共识[J]. 中国口腔颌面外科杂志, 2015, 13(3):262-269.
[2] 王祥军, 李新明, 王清之, 等. 口腔黏膜黑色素瘤病理误诊和颈淋巴结转移研究[J]. 医药论坛杂志, 2012, 33(3):82-83.
[3] Ordonez NG. Value of melanocytic-associated immunohistochemical markers in the diagnosis of malignant melanoma: a review and update[J]. Hum Pathol, 2014, 45(2):191-205.
[4] Shakhova O, et al. Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma[J]. Nat Cell Biol, 2012, 14(8):882-890.
[5] 陈飞. 恶性黑色素瘤的临床病理特点分析[J]. 临床合理用药杂志, 2017, 10(21):100-101.
[6] 管春鸾, 皮肤恶性黑色素瘤临床病理分析[J]. 中国继续医学教育, 2015, 7(27):67-68.
[7] Nonaka D, Chiriboga L, Rubin BP. Sox10: a pan-schwannian and melanocytic marker[J]. Am J Surg Pathol, 2008, 32(9):1291-1298.
[8] Miettinen M, et al. Sox10--a marker for not only schwannian and melanocytic neoplasms but also myoepithelial cell tumors of soft tissue: a systematic analysis of 5134 tumors[J]. Am J Surg Pathol, 2015, 39(6):826-835.
[9] Liu H.G, et al. Expression of Sox10 and c-kit in sinonasal mucosal melanomas arising in the Chinese population[J]. Head Neck Pathol, 2012, 6(4):401-408.
[10] Rochaix P, et al. PNL2, a new monoclonal antibody directed against a fixative-resistant melanocyte antigen[J]. Mod Pathol, 2003, 16(5):481-490.
[11] Kaufmann O, et al. Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections[J]. Mod Pathol, 1998, 11(8):740-746.
[12] Reinke S, et al. Differential expression of MART-1, tyrosinase, and SM5-1 in primary and metastatic melanoma[J]. Am J Dermatopathol, 2005, 27(5):401-406.
[13] Plaza JA, Suster D, Perez-Montiel D. Expression of immunohistochemical markers in primary and metastatic malignant melanoma: a comparative study in 70 patients using a tissue microarray technique[J]. Appl Immunohistochem Mol Morphol, 2007, 15(4):421-425.
[14] Ordonez NG, Ji XL, Hickey RC. Comparison of HMB-45 monoclonal antibody and S-100 protein in the immunohistochemical diagnosis of melanoma[J]. Am J Clin Pathol, 1988, 90(4):385-390.
[15] Shah IA, Gani OS, Wheler L. Comparative immunoreactivity of CD-68 and HMB-45 in malignant melanoma, neural tumors and nevi[J]. Pathol Res Pract, 1997, 193(7):497-502.
[16] Orchard GE. Comparison of immunohistochemical labelling of melanocyte differentiation antibodies melan-A,tyrosinase and HMB 45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma[J]. Histochem J, 2000, 32(8):475-481.
[17] Miettinen M, Fernadez M, Franssila k, et al. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers[J]. Am J Surg Pathol, 2001, 25(2):205-211.
[18] Granter SR, Weibacher KN, Quigley C, et al. Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma[J]. Appl Immunohistochem Mol Morphol, 2002, 10(1):47-51.
[19] Ohsie SJ, Sarantopoulos GP, Cochran AJ, et al. Immunohistochemical characteristics of melanoma[J]. J Cutan Pathol, 2008, 35(5):433-444.
[20] Gershon TR, Oppenheimer O, Chin SS, et al. Temporally regulated neural crest transcription factors distinguish neuroectodermal tumors of varying malignancy and differentiation[J]. Neoplasia, 2005, 7(6):575-584.
[21] Agnarsdottir M, Sooman L, Bolander A, et al. SOX10 expression in superficial spreading and nodular malignant melanomas[J]. Melanoma Res, 2010, 20(6):468-478.
[22] Ramos-Herberth FI, Karamchandami J, Kim J, et al. SOX10 immunostaining distinguishes desmoplastic melanoma from excision scar[J]. J Cutan Pathol, 2010, 37(9):944-952.
[23] Jennings C, Kim J. Identification of nodal metastases in melanoma using sox-10[J]. Am J Dermatopathol, 2011, 33(5): 474-82.
[24] Mohamed A, Gonzalez RS, Lauson D, et al. SOX10 expression in malignant melanoma, carcinoma, and normal tissues[J]. Appl Immunohistochem Mol Morphol, 2013, 21(6):506-510.
[25] Wu Y, Wang L, Max X, et al. The existence of early stage oral mucosal melanoma: A 10-year retrospective analysis of 170 patients in a single institute[J]. Oral Oncol, 2018, 87:70-76.
[26] Plaza JA, Bonnean P, Prieto V, et al. Desmoplastic melanoma: an updated immunohistochemical analysis of 40 cases with a proposal for an additional panel of stains for diagnosis[J]. J Cutan Pathol, 2016, 43(4):313-323.
[27] Tacha D, Qi W, Ra S, et al. A newly developed mouse monoclonal SOX10 antibody is a highly sensitive and specific marker for malignant melanoma, including spindle cell and desmoplastic melanomas[J]. Arch Pathol Lab Med, 2015, 139(4):530-536.
[28] Palla B, Su A, Binder S, et al. SOX10 expression distinguishes desmoplastic melanoma from its histologic mimics[J]. Am J Dermatopathol, 2013, 35(5):576-581.
[29] Mǎrgǎritescu I, AD. Desmoplastic melanoma--challenges in the diagnosis and management of a rare cutaneous tumor[J]. Rom J Morphol Embryol, 2014, 55(3):947-952.
[30] Otaibi S, Jukic DM, Drogowski L, et al. NGFR (p75) expression in cutaneous scars; Further evidence for a potential pitfall in evaluation of reexcision scars of cutaneous neoplasms, in particular desmoplastic melanoma[J]. Am J Dermatopathol, 2011, 33(1):65-71.
[31] Lazova R, Tantcheva-Poor I, Sigal AC. P75 nerve growth factor receptor staining is superior to S100 in identifying spindle cell and desmoplastic melanoma[J]. J Am Acad Dermatol, 2010, 63(5):852-858.
[32] Jou A, Miranda FV, Oliveira MG, et al. Oral desmoplastic melanoma mimicking inflammatory hyperplasia[J]. Gerodontology, 2012, 29(2):163-167.
[33] Godoy GP, de Castro Gomes DQ, Pereir JV, et al. Desmoplastic melanoma of the lower lip: a case report[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2009, 108(5):e64-69.

选择文件类型/文献管理软件名称

选择包含的内容